Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis

  • By

  • November 16, 2026

  • 7 min

Share

Clinical Scorecard: Fibrotic Pericytes and FOXF1 in Pulmonary Fibrosis

At a Glance

CategoryDetail
ConditionPulmonary fibrosis, including fibrosis associated with pediatric hematopoietic cell transplantation (HCT)
Key MechanismsA pericyte subset found in fibrotic lungs expresses scar-related genes and reduced FOXF1. In preclinical experiments, pericyte FOXF1 influenced signaling to fibroblasts and lung fibrosis.
Target PopulationPeople with pulmonary fibrosis; pediatric HCT recipients are a clinical context discussed in the article. The FOXF1 findings are preclinical.
Care SettingPulmonology and post-HCT care; the reported FOXF1 target findings come from human lung datasets, laboratory experiments, and mouse models, not clinical treatment trials.

Key Highlights

  • Single-cell analysis identified Peri2 pericytes in fibrotic, but not healthy, lungs; these cells expressed collagen and other scar-related genes.
  • Reduced FOXF1 in pericytes was observed in human pulmonary fibrosis data and in mice with lung injury.
  • In mouse models, removing pericyte FOXF1 worsened fibrosis, while raising it reduced fibrosis and improved measured outcomes, including oxygen levels.
  • Laboratory experiments indicated that pericytes can influence fibroblast movement, proliferation, and scar-related gene activity.
  • The findings are preclinical and do not establish that FOXF1-directed treatment benefits patients.

Guideline-Based Recommendations

Diagnosis

  • The article describes Peri2 identification using single-cell RNA sequencing and confirmation with tissue staining; it does not provide a clinical diagnostic recommendation.

Management

  • The article reports that nintedanib, pirfenidone, and nerandomilast slow lung-function loss, but does not show restoration of lung architecture.
  • Lung transplantation is described as the only option that changes the disease course for eligible patients.
  • FOXF1-directed approaches are investigational; the article states that clinical trials must support the research direction.

Monitoring & Follow-up

  • The article provides no FOXF1-specific patient monitoring protocol.
  • It reports that post-HCT pulmonary fibrosis may appear years after transplant; PPFE is described as typically appearing several years after HCT.

Risks

  • The article describes pediatric HCT-associated PPFE as often fatal and reports an association with post-transplant pneumonia (hazard ratio 10.78).
  • Conditioning-regimen toxicity, including busulfan, and chronic graft-versus-host disease are described as possible causes of chronic interstitial pneumonia with fibrosis.
  • The article notes that FOXF1 functions in other cell types, making safety assessment necessary for potential targeted treatment.

Patient & Prescribing Data

The human analysis included a public single-cell dataset of 49 donor lungs and 67 pulmonary fibrosis lungs. The article also discusses pediatric HCT recipients; it provides no patient prescribing cohort for FOXF1-directed treatment.

No FOXF1-directed treatment has been established for patients. Raising FOXF1 reduced fibrosis in mice, including when initiated after scarring began; the article states that patient benefit has not been demonstrated.

Clinical Best Practices

  • Interpret the FOXF1 findings as preclinical rather than evidence of an effective patient treatment.
  • The article identifies post-HCT pulmonary fibrosis as a clinical concern and describes PPFE as a fibrotic complication reported in pediatric HCT recipients.
  • Before clinical trials, the article identifies further work on drug targets, testing in patient lung tissue and additional animal models, pericyte-specific delivery, and safety.

Related Resources & Content

Original Source(s)

Related Content